@LT_Investor
It depends if cash receipts will be maintained at $14.6m, reduce through seasonality or increase in line with ARR over the next 12 months. Based on current ARR of $62.8m, cash receipts should reach $15.7m per quarter on average.
I think what's interesting (based on the most recent quarter), is it seems like much of the lag between ARR and cash collection has reduced. I always thought it was strange that there was such a large delay between ARR and cash receipts. The only thing I can put it down to is the acquisitions inorganically boosting ARR (and seasonal payment cycles from those customers) and the conclusion of the N3 partnership distorting cash collection numbers. Hopefully things will be more predictable now that we're clear of all of those events.
In terms of current op ex, I'd be keen to understand if the R&D costs incurred this past quarter are recurring or were just a one-off increase as they invested upfront. Most other costs seem to have normalised.
- Forums
- ASX - By Stock
- LVT
- Ann: FY21 Q4 Quarterly Activities Report and Appendix 4C
Ann: FY21 Q4 Quarterly Activities Report and Appendix 4C, page-42
-
-
- There are more pages in this discussion • 125 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LVT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online